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Abstract: The United States has a deficit of rheumatology specialists. This leads to an increased
burden in accessing care for patients requiring specialized care. Given that most rheumatologists
are located in urban centers at large hospitals, many lupus patients must travel long distances for
routine appointments. The present work aims to determine whether travel burden is associated with
increased levels of depression and anxiety among these patients. Data for this study were collected
from baseline visits of patients participating in a lupus study at MUSC. A travel/economic burden
survey was assessed as well as the 8-item Patient Health Questionnaire (PHQ-8) and the 7-item
Generalized Anxiety Disorder (GAD-7) survey as measures of depression and anxiety, respectively.
Linear regression models were used to assess the relationship between travel burden and depression
and anxiety. Frequency of healthcare visits was significantly associated with increased depression
(β = 1.3, p = 0.02). Significant relationships were identified between anxiety and requiring time off
from work for healthcare appointments (β = 4, p = 0.02), and anxiety and perceived difficulty in
traveling to primary care providers (β = 3.1, p = 0.04). Results from this study provide evidence that
travel burden can have an effect on lupus patients’ anxiety and depression levels.
Keywords: systemic lupus erythematosus (SLE); PHQ-8; GAD-8; anxiety; depression
1. Introduction
It is estimated that 1.5 million Americans have some form of lupus [1]. Globally,
systemic lupus erythematosus (SLE) is estimated to effect at least five million individuals,
with more than 100,000 new cases developing every year [2–5]. SLE and other autoimmune
diseases are identified when one’s immune system loses its ability to differentiate between
foreign substances and its own cells and tissues, causing the body to attack itself. SLE
has a wide spectrum of clinical presentations, which are characterized by remissions and
exacerbations. SLE can affect any part of the body (e.g., skin, joints, blood, and kidneys)
and can be life-threatening [6]. Vital organs are affected by lupus, including alterations in
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the heart, lungs, and brain, which can result in morbidity for patients. In the United States,
the highest lupus morbidity and mortality rates are among African American women [7–9].
Specifically, SLE affects approximately 1 in 250 African American women of childbearing
age, who have three to four times higher prevalence of SLE; are at risk for developing SLE
at an earlier age; and have increased SLE-related disease activity, damage, and mortality
compared to White Americans [10–13].
Unfortunately, healthcare providers who are well-versed in the care for those diag-
nosed with SLE are sparse (e.g., rheumatologists). In an assessment of rheumatologists’
workforce in 2015, there were 4497 board certified rheumatologists [14]. However, there
was an estimated shortage of 1118 rheumatologists based on patient need for this spe-
cialty [14]. Moreover, it is projected that by 2030, there will be a demand for an estimated
8149 rheumatologists [14]. Even with an increase in board certified rheumatologists, there
is a projected shortage of rheumatologist of 4729 [14]. The shortage of rheumatologists
makes health-related travel increasingly difficult for SLE patients who require their care.
In previous research, health-related travel has been investigated as a potential barrier
to accessing health care and has been shown to lead to rescheduled or missed appointments,
delayed care, and low medication adherence [15,16]. Low medication adherence, particu-
larly among African American women, has been shown to be associated with depressive
symptoms [17]. Depression has been shown to have a significant positive correlation with
organ damage in African American women with SLE [18]. Furthermore, compared to
White Americans, African Americans are more likely to experience psychosocial stressors,
and depression can increase levels of stress and anxiety, which then may induce flares and
worsen SLE symptoms [19,20]. However, there is limited information on whether travel
burden to receive health care influences depression and anxiety among those diagnosed
with SLE [15,20]. Therefore, the objective of this study was to evaluate the impact of travel
burden on depression and anxiety among African American women with SLE.
2. Materials and Methods
For the current study, data from a study that aimed to test the effectiveness of socio-
behavioral interventions for SLE patients in South Carolina were utilized. Only baseline
(pre-intervention) data were utilized for this study to negate the potentially confounding
impacts the interventions may have had on the treatment groups. The Peer Approaches
to Lupus Self-Management (PALS) study was conducted with two cohorts, though both
participated in peer support interventions (IRB# Pro00080875). A detailed description of
the PALS protocol for this study has been published elsewhere [21]. PALS was approved
by the IRB at the Medical University of South Carolina (MUSC). Study participants in the
study provided written informed consent prior to engaging in study activities.
2.1. Study Participants and Recruitment
The PALS study largely enrolled SLE patients seen within the MUSC health system.
However, individuals from the broader patient population in South Carolina were also
included through referrals and advertisements placed throughout the community. All
SLE patients included in PALS were African American women, over the age of 18, and
could communicate in English. Excluded from the study were subjects with cognitive
impairments, substance user disorders, and comorbid conditions that could impact their
ability to communicate effectively (e.g., blindness or deafness).
2.2. Outcome Measures
Subjects in PALS completed questionnaires prior to taking part in any intervention
activities. Outcomes of interest for this study included depression—measured by the Pa-
tient Health Questionnaire-8 (PHQ-8) [22], anxiety—measured by the Generalized Anxiety
Disorder-7 (GAD-7) [23], and medical travel burden—assessed by a purpose-built survey.
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2.3. Statistical Methods
Descriptive data for outcomes measure are presented. We ran unadjusted and adjusted
linear regression models using the total PHQ-8 score or total GAD-7 score as the outcome
variables. The adjusted model accounted for question 3 of the Systemic Lupus Activity
Questionnaire (SLAQ). The SLAQ is a self-reported disease activity measure for SLE
patients. Question 3 of the measure asks subjects to rate their disease activity in the
previous 3-months on a 0—10 scale, where zero represents no activity and ten indicates
highly active disease symptomology [24]. Statistical significance was determined when
p < 0.05.
3. Results
The current analysis included baseline data from 100 SLE patients who participated in
the PALS study (see Table 1). All study participants were African American women with
a median age category of 25–34 years. The majority of study participants had a college
degree (38.6%) and health insurance (92.1%). A little less than half were unemployed
(46.1%). Baseline assessments for depression revealed that PALS participants reported a
mean score on the PHQ-8 of 8.62 (±5.79), a baseline anxiety of 7.96 (±6.33) and an average
self-reported disease activity measure by SLAQ of 5.30 (±2.74).










Less than high school 8 (9.1)
High School Grad 15 (17.0)
Some College 31 (35.2)
College Grad 34 (38.6)
Income (%)
<$15 K 28 (31.5)
$15–$34.9 K 18 (20.2)
$35–$64.9 K 16 (18.0)
> or = $65 K 9 (10.1)
Other/don’t want to respond 18 (20.2)
Not married (%) 73 (82.0)
Unemployed (%) 41 (46.1)
Insured (%) 82 (92.1)
An assessment of healthcare-related travel burden at baseline revealed that only 9%
of all study participants found it difficult or very difficult to travel to primary care visits.
Perceived difficulty in traveling to rheumatology appointment was somewhat higher, with
13.7% of participants reporting that it was either difficult or very difficult to travel for
those visits. Moreover, participants reported a mean travel distance of nearly 65.5 (±60.7)
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miles to their rheumatologist and that that travel took more than 70.3 (±64) minutes. Most
participants (57.6%) reported that they traveled to between 1 and 2 healthcare-related
appointments per week, and just over half (51.2%) indicated that their health insurance
covers medical transportation. Similarly, 47.1% reported that it was either easy or very easy
to arrange that transportation. Conversely, subjects reported missing on average about 2
(±6.57) appointments in the last year due to travel issues (see Table 2).
Table 2. Access to Healthcare and Travel Burden Characteristics.
n 100
Difficulty Traveling to Primary Care Provider (%)




Very Easy 37 (41.6)
Difficulty Traveling to Rheumatologist (%)




Very Easy 32 (36.4)
Travel Issues Make Keeping Appointments Difficult (%)




Very Easy 22 (25.3)







Insurance Covers Medical Transportation (%) 43 (51.2)
Difficulty Scheduling Medical Transportation (%)




Very Easy 12 (22.6)
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Table 2. Cont.
n 100
Have to Take Time Off for Doctors’ Appointments (%) 50 (56.2)
Travel Affects Keeping Appointments (%) 0.30 (0.46)
Distance (in miles) to Rheumatologist (mean (SD)) 65.47 (60.69)
Commute Time (in minutes) to Lupus Care (mean (SD)) 70.33 (64.00)
Number of Appointments Missed as a Result of Transportation
Issues (mean (SD)) 2.26 (6.57)
Depression (PHQ-8) (mean (SD)) 8.62 (5.79)
Anxiety (GAD-8) (mean (SD)) 7.96 (6.33)
SLAQ (mean (SD)) 4.56 (2.47)
Linear regression models were used to assess the relationship between travel burden
and depression and anxiety. Table 3 details the unadjusted model for the relationship
between travel burden and depression. Frequency of healthcare visits was significantly
associated with an increased PHQ-8 score (β = 1.6, p = 0.005). After adjusting for self-
reported disease activity (SLAQ question 3), the relationship between travel burden and an
additional healthcare visit remained statistically significant (β = 1.4, p = 0.01) and having
to take time off for doctors’ appointments became statistically significant (β = 3, p = 0.03).
After adjusting for disease activity, age, employment, income, and insurance, frequency of
healthcare visits (β = 1.3, p = 0.02) and having to take time off for doctors’ appointments
(β = 5.3, p = 0.03) remained significant (see Table 3).
Table 3. Linear Regression Model of the Effect of Travel Burden Indicators on Depression (PHQ8).
Model 1 a Model 2 b Model 3 c
β (95%CI) p-Value β (95%CI) p-Value β (95%CI) p-Value
Difficulty Traveling to
Primary Care Provider 0.1 (−2.4, 2.6) 0.94 −0.1 (−2.8, 2.5) 0.9256 0.6 (−2.1, 3.3) 0.65
Difficulty Traveling to
Rheumatologist −1.6 (−4, 0.8) 0.19 −0.9 (−3.4, 1.6) 0.4565 −1.7 (−4.2, 0.9) 0.20
Distance (in miles) to
Rheumatologist −0.04 (−0.1, 0.02) 0.16 −0.03 (−0.1, 0.03) 0.2742 −0.02 (−0.1, 0.04) 0.45
Commute Time (in




−0.4 (−2.2, 1.5) 0.69 −0.6 (−2.5, 1.3) 0.5256 −0.3 (−2.3, 1.8) 0.78
Frequency of Health Care
Visits in a Week 1.6 (0.5, 2.6) 0.005 1.4 (0.3, 2.4) 0.0113 1.3 (0.2, 2.5) 0.02
Insurance Covers
Medical Transportation −1.2 (−3.9, 1.5) 0.38 −1.4 (−4.2, 1.3) 0.3038 −1.9 (−5, 1.2) 0.23
Have to Take Time Off for
Doctors’ Appointments 2.6 (−0.2, 5.4) 0.067 3 (0.3, 5.7) 0.0321 5.3 (1.8, 8.8) 0.003
Travel Affects Keeping
Appointments 0.4 (−3.2, 4) 0.81 1 (−2.7, 4.7) 0.586 0.8 (−2.9, 4.5) 0.66
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Table 3. Cont.
Model 1 a Model 2 b Model 3 c
β (95%CI) p-Value β (95%CI) p-Value β (95%CI) p-Value
Number of Appointments
(in one year) Missed as a
Result of
Transportation Issues
0.1 (−0.2, 0.3) 0.65 0.02 (−0.2, 0.3) 0.8541 0.1 (−0.2, 0.3) 0.66
Transportation Issues
Increase Stress −0.6 (−3.5, 2.3) 0.68 −0.4 (−3.2, 2.4) 0.7618 −0.7 (−3.5, 2.1) 0.63
SLAQ 0.7 (0.1, 1.2) 0.0144 0.7 (0.1, 1.2) 0.014
Age −0.3 (−1.4, 0.8) 0.63
Employment −3.5 (−7.2, 0.2) 0.06
Income 0.3 (−0.6, 1.2) 0.48
Insurance −3.8 (−10.3, 2.76) 0.25
a Unadjusted; b Adjusting for disease activity using SLAQ.; c Adjusting for disease activity using SLAQ, Age, Employment, and Insurance.
Table 4 displays the unadjusted model when examining the effect of anxiety on travel
burden. There was no statistically significant relationship between anxiety and travel
in the unadjusted model. However, when controlling for disease activity, a statistically
significant relationship was found between anxiety and requiring time off from work for
healthcare appointments (β = 3.1, p = 0.03). In the model adjusting for disease activity, age,
employment, and income, perceived difficulty in arranging transportation to healthcare
appointments was found to have a statistically significant relationship with anxiety (β = 3.1,
p = 0.04) (see Table 4). In addition, requiring time off from work remained significant (β = 4,
p = 0.02).
Table 4. Linear Regression Model of the Effect of Travel Burden Indicators on Anxiety (GAD8).
Model 1 a Model 2 b Model 3 c
β (95%CI) p-Value β (95%CI) p-Value β (95%CI) p-Value
Difficulty Traveling to
Primary Care Provider 1.14 (−1.6, 3.9) 0.41 2.2 (−0.8, 5.1) 0.14 3.1 (0.1, 6.1) 0.04
Difficulty Traveling to
Rheumatologist −1.7 (−4.3, 1) 0.21 −1.8 (−4.5, 0.9) 0.18 −2.54 (−5.2, 0.2) 0.07
Distance (in miles) to
Rheumatologist −0.03 (−0.1, 0.02) 0.25 −0.02 (−0.1, 0.04) 0.60 −0.002 (−0.1, 0.06) 0.96
Commute Time (in minutes)
to Lupus Care 0.01 (−0.05, 0.1) 0.72 −0.003 (−0.06, 0.1) 0.92 −0.02 (−0.07, 0.04) 0.51
Travel Issues Make Keeping
Appointments Difficult 0.3 (−1.6, 2.2) 0.76 −0.3 (−2.3, 1.6) 0.74 0.3 (−1.7, 2.3) 0.76
Frequency of Health Care
Visits in a Week 0.7 (−0.4, 1.7) 0.21 0.6 (−0.4, 1.7) 0.23 0.5 (−0.6, 1.6) 0.34
Insurance Covers Medical
Transportation 3 (−0.7, 6.8) 0.11 2.9 (−0.7, 6.6) 0.11 0.2 (−4.2, 4.6) 0.92
Difficulty Scheduling
Medical Transportation −0.3 (−1.9, 1.2) 0.68 −0.1 (−1.6, 1.4) 0.93 0.1 (−1.4, 1.5) 0.95
Have to Take Time Off for
Doctors’ Appointments 2.4 (−0.5, 5.3) 0.10 3.1 (0.2, 5.9) 0.03 4 (0.5, 7.5) 0.02
SLAQ 0.52 (−0.1, 1.1) 0.10 0.04 (−0.02, 0.1) 0.20
Age 0.1 (−1, 1.2) 0.90
Employment −2.7 (−6.8, 1.3) 0.18
Income −0.9 (−1.8, −0.02) 0.05
a Unadjusted.; b Adjusting for disease activity using SLAQ. c Adjusting for disease activity using SLAQ, Age, Employment, and Insurance.
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4. Discussion
This study provides several key findings. First, travel burden had a significant effect
on SLE patients’ self-reported depression. Second, requiring time off work for medical
appointments showed a significant increase in SLE patients’ anxiety. Third, perceived
difficulty in arranging medical transportation had an inverse statistically significant rela-
tionship with anxiety. Overall, the findings of this study seem to indicate that travel burden
has a significant effect on depression and anxiety among African American women living
with SLE.
These findings are consistent with a systematic review by Zhang et al. [25] that sug-
gests that the prevalence of depression and anxiety is high in adult SLE patients. In
addition, a meta-analysis by Moustafa et al. [26] found that depression and anxiety among
SLE patients reached 78.6% and 71.6%, respectively. The results of the current study found
that frequency of healthcare visits was significantly associated with an increased depression
score. This is also consistent with literature that shows the relationship between depression
and increased healthcare utilization in the United States. Of note, an estimated 85% of
those living with depression are also living with one or more chronic conditions, and
approximately 30% have four or more chronic conditions. Taken together, the resulting
healthcare utilization results in those with depression is more than two times the healthcare
costs of those who have not been diagnosed with depression [27]. The literature also
recommends that rheumatologists screen for depression among SLE patients and make
appropriate referrals to mental health services [25]. Though there was no statistically sig-
nificant relationship between travel burden and anxiety, there was a statistically significant
relationship between anxiety and requiring time off from work for healthcare appointments
and perceived difficulty in arranging transportation to healthcare appointments.
In addition to the significant findings in this study, we recognize that there were
a few limitations. First, this study used a small sample size (N = 100). Though this
has been considered a limitation, the prevalence of SLE is not as high as other, more
common chronic conditions, and the study sample reflects this distinction. Second, all
study participants were African American women that mostly reside in a concentrated
area of the southeast United States. These two factors may limit generalizability of study
findings. Future research should consider a larger study population using a more regionally
diverse population to determine if findings remain consistent.
5. Conclusions
In summary, these results show that there is a relationship between travel burden
and depression and anxiety in African American women with SLE. This is important
because travel burden remains a significant barrier to care for many SLE patients. Not
only does inadequate access to care lead to greater direct healthcare costs but it can
also result in the development or worsening of comorbid conditions. Compounding
chronic conditions further complicate the treatment process for these patients and impede
appropriate resource delivery.
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